Comparative Pharmacology
Head-to-head clinical analysis: GANTRISIN PEDIATRIC versus SULFAPYRIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTRISIN PEDIATRIC versus SULFAPYRIDINE.
GANTRISIN PEDIATRIC vs SULFAPYRIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfisoxazole is a competitive inhibitor of bacterial dihydropteroate synthase, preventing the incorporation of para-aminobenzoic acid (PABA) into dihydrofolate, thereby inhibiting bacterial folic acid synthesis.
Sulfapyridine is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production. It also has anti-inflammatory and immunomodulatory effects in dermatologic conditions through unknown mechanisms.
2-4 g initially, then 4-6 g/day in 3-6 divided doses orally, depending on severity. Alternatively, for sulfisoxazole (the active moiety), typical adult dose is 500 mg to 1 g orally every 6 hours. IM use: 50 mg/kg initially, then 100 mg/kg/day in divided doses every 6-8 hours. IV use: Not recommended in pediatric formulation.
500 mg orally four times daily for initial treatment of dermatitis herpetiformis; maintenance dose 500 mg daily to 1.5 g daily in divided doses.
None Documented
None Documented
Clinical Note
moderateSulfapyridine + Mecamylamine
"The risk or severity of adverse effects can be increased when Sulfapyridine is combined with Mecamylamine."
Clinical Note
moderateDexketoprofen + Sulfapyridine
"The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfapyridine."
Terminal elimination half-life is 6-12 hours (prolonged in renal impairment; up to 30 hours in patients with creatinine clearance <10 mL/min).
Terminal elimination half-life: 6–10 hours (prolonged in renal impairment or slow acetylators); clinical context: requires dosing adjustment in renal insufficiency.
Primarily renal (70-100% as unchanged drug and acetylated metabolites) via glomerular filtration and tubular secretion; <10% fecal.
Renal: approximately 70–80% (30% as unchanged drug, remainder as metabolites, primarily N4-acetylsulfapyridine); biliary/fecal: minor (<5%).
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic